

Öffentlicher Titel	Beobachtungsstudie zu Blinatumomab bei B-ALL
Wissenschaftl. Titel	An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices
Kurztitel	20150136
Studennummer KN/ELN	LN_NN_2019_647
Studiengruppe	NN
Studienart	Beobachtungsstudie, multizentrisch, einarmig, prospektiv, offen
Studienphase	nicht zutreffend
Erkrankung	Akute lymphatische Leukämie (ALL) - B-Vorläufer ALL
Leukämiestadium	rezidiert/refraktär molekulares Rezidiv
Einschlusskriterien	<ul style="list-style-type: none">- Medical records of patients initiating Blincyto after country-specific reimbursement in routine clinical practice will be eligible for abstraction.
Ausschlusskriterien	<ul style="list-style-type: none">- Medical records of patients who have participated in Blincyto clinical trials will be excluded since their treatment will be prescribed by the study protocol unless the patient is receiving new Blincyto treatment outside the clinical trial- Medical records of patients participating in other Amgen non-interventional prospective studies in which safety endpoints are collected will be excluded- Medical records of patients who have received Blincyto via an expanded access/compassionate use program will be excluded- In countries where patient informed consent is required for access to their medical records, any patient who does not provide informed consent will be excluded
Alter	>= 18 Jahre
Status	Aktiv
Beginn der Rekrutierung	26.02.2019
Sponsoren	Amgen Inc.
Registrierung in anderen Studienregistern	ClinicalTrials.govNCT03117621